Back to top
more

Range Cancer Therapeutics ETF: (CNCR)

(Delayed Data from NASDAQ) As of Sep 20, 2024 03:59 PM ET

$15.64 USD

15.64
6,006

-0.15 (-0.95%)

Volume: 6,006

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

2 - Buy of 5   2      

Zacks News

Sweta Killa headshot

5 ETFs That Led the Rebound on Monday

Wall Street roars back from its biggest weekly losses of the year, driven by bargain hunting and looming Fed rate cuts.

Sanghamitra Saha headshot

Best-Performing ETF Areas of Past Week

Wall Street was upbeat last week on Fed rate cut hopes.

Sweta Killa headshot

5 Top-Ranked ETFs to Buy at a Bargain

After a three-day rout, Wall Street staged a solid comeback as investors bought beaten-down stocks and recession fears eased. To tap the beaten-down prices, we have highlighted five ETFs from different corners that have declined over the past week and have a solid Zacks ETF Rank.

Sanghamitra Saha headshot

Best ETFs of Last Week

Wall Street offered a mixed performance last week.

Sanghamitra Saha headshot

Time for Healthcare ETFs?

Compelling valuation, innovation in specific growth areas and an aging population as well as increasing healthcare spending are the tailwinds of the medical sector.

Sanghamitra Saha headshot

5 Top ETFs of Last Week

Wall Street was moderately upbeat last week

Sweta Killa headshot

3 Top-Ranked ETFs Under $20 for Your Portfolio

Low-priced stocks could be attractive as these will enable them to buy more shares instead of just a handful of higher-priced shares for the same amount.

Sanghamitra Saha headshot

Best ETF Areas of Last Week

Wall Street was upbeat last week. The Fed's plan to slower the balance sheet tightening process and the release of downbeat jobs data dragged down bond yields.

The Zacks Analyst Blog Highlights CRPT, WEED, SMH, CNCR and KBWP

CRPT, WEED, SMH, CNCR and KBWP are part of the Zacks top Analyst Blog.

Sweta Killa headshot

5 Market-Beating Sector ETFs of Q1

Wall Street is set to wrap up the first quarter with strong gains. The gains were broad-based and well spread out across various segments.

Sanghamitra Saha headshot

Top & Flop ETF Areas of Wall Street's Best February in Decade

Wall Street surged to close out February with the S&P 500 and Nasdaq Composite notching their best February since 2015.

The Zacks Analyst Blog Highlights CRPT, CNCR, WISE, AIRR and PKB

CRPT, CNCR, WISE, AIRR and PKB are part of the Zacks top Analyst Blog.

Sweta Killa headshot

5 Best-Performing Sector ETFs of February

The gains were broad-based and well spread out across various segments. We have highlighted some of the top performers in the ETF space from different sectors of the market.

Sweta Killa headshot

5 Sector ETFs Beating the Market Halfway Through Q1

A combination of factors, including a solid earnings season, a resilient economy and a technology surge, powered the rally, resulting in a gain of about 5% for the S&P 500 Index this year.

Sanghamitra Saha headshot

5 ETF Areas That Spooked Investors in October

After a downbeat September, October too remained volatile for Wall Street due to higher rates.

Sanghamitra Saha headshot

Inside Tema ETFs' New Oncology ETF (CANC)

Oncology treatment has witnessed remarkable progress due to the relentless efforts of pharmaceutical companies in recent times.

Sanghamitra Saha headshot

Best & Worst Sector ETFs of First-Half 2023

These sector ETFs have won and lost the most in the first half of 2023.

Sweta Killa headshot

5 Top-Ranked ETFs to Buy at Bargain Prices for 2023

Concerns over higher inflation and rising rates continued to weigh on investors' sentiments. This has provided a compelling opportunity for investors to buy cheap heading into 2023.

The Zacks Analyst Blog Highlights BBC, CNCR XBI, BBP, and SBIO

BBC, CNCR, XBI, BBP, and SBIO are part of Zacks top Analyst Blog.

Sweta Killa headshot

5 ETFs Riding High on the Biotech Comeback

Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.

Sanghamitra Saha headshot

Pharma & Biotech ETFs at One-Month High: Here's Why

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

Sweta Killa headshot

Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News

The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.

Neena Mishra headshot

Best Biotech Stocks & ETFs for mRNA, Gene Editing

Here is what you should know about investing in these life changing technologies.

Sweta Jaiswal, FRM headshot

Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.

Sweta Jaiswal, FRM headshot

A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.